trending Market Intelligence /marketintelligence/en/news-insights/trending/w82np1h9tpm0ywjds1jv3q2 content esgSubNav
In This List

EyeGate Pharmaceuticals names director

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


EyeGate Pharmaceuticals names director

EyeGate Pharmaceuticals Inc. appointed Steven Boyd to its board.

Boyd is the chief investment officer of Armistice Capital, a New York-based equity hedge fund focused on the healthcare and consumer sectors.

Waltham, Mass.-based EyeGate is a clinical-stage specialty pharmaceutical company developing therapies to treat eye-related diseases and disorders.